NorthWest Biotherapeutics Inc (NWBO)

[Investor082]

BS. Eden wont be approved until mid 2026 at the earliest. That too is the best case scenario and with NWBO that almost always never works out.

Then they need another year to prepare application for US. Then another 9 months for approval. So mid 2028 at the earliest for FDA approval. Then at least another year for reimbursement and payer access in the US. So mid 2029 before they start generating meaningful revenue in the most important market. Other jurisdictions wont matter that much. US alone contributes to over 50% of the global oncology immunotherapy revenue.

At this point, NWBO may deserve $5-6B market cap valuation. But the share count would be at least 2.5 to 3B by then. So about $2 in share price by 2030. That too everything must go according to plan and thats too much to expect from this crew.

I’d rather take .50 cents at UK approval later this quarter and invest in a company that is well managed and backed by a solid team and institutional investors. Less risky and can potentially get better return.